| Name | Title | Contact Details |
|---|
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.
MicroBiotix is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.